Dr. Panmai is currently working at WuXi STA as Vice President and Head of Early-phase Formulation Development, where he has been since 2017. He leads the formulation teams in Shanghai and Wuxi city, China, which are responsible for formulation development and clinical trial materials of new chemical entities from global clients (US, Europe and Asia).
Prior to joining WuXi STA, he worked at MSD in the US (PA/NJ) for 18 years in the Pharmaceutical Sciences group. He has extensive experience in formulation development and material characterization.
Dr. Panmai obtained his B.S. in Chemical Engineering from the University of California at Berkeley and Ph.D. in Chemical Engineering from Princeton University.
WuXi STA, a subsidiary of WuXi AppTec, is a leading CRDMO providing integrated CMC services including both API and drug product for small molecule, oligonucleotide, peptide and complex conjugate from discovery to development and commercial manufacturing.
WuXi STA has 13 R&D and manufacturing sites across Asia, North America and Europe. Our comprehensive drug product platform has a strong R&D team of 1200+ scientists with capabilities in broad oral and parenteral dosage forms. Our bioavailability enhancement technology platform includes spray-dried dispersion, hot melt extrusion, nano suspension, softgel & liquid filled hard capsules.